Central Trust CO Bristol Myers Squibb CO Transaction History

Central Trust CO

$4 Billion
Q4 2024

A detailed history of Central Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Central Trust CO holds 137,365 shares of BMY stock, worth $7.89 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

137,365

Previous 145,689 5.71%

Holding current value

$7.89 Million

Previous $7.54 Million 3.05%

% of portfolio

0.19%

Previous 0.18%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 24, 2025	SELL	$51.92 - $59.94 $432,182 - $498,940	-8,324 Reduced 5.71%	137,365 $7.77 Million
Q3 2024 Oct 22, 2024	SELL	$39.66 - $51.75 $119,574 - $156,026	-3,015 Reduced 2.03%	145,689 $7.54 Million
Q2 2024 Aug 05, 2024	SELL	$40.25 - $52.99 $746,999 - $983,441	-18,559 Reduced 11.1%	148,704 $6.18 Million
Q1 2024 Apr 24, 2024	SELL	$47.98 - $54.4 $551,530 - $625,328	-11,495 Reduced 6.43%	167,263 $9.07 Million
Q4 2023 Jan 24, 2024	SELL	$48.48 - $57.85 $1.18 Million - $1.41 Million	-24,390 Reduced 12.01%	178,758 $9.17 Million
Q3 2023 Oct 26, 2023	SELL	$57.89 - $64.73 $772,715 - $864,016	-13,348 Reduced 6.17%	203,148 $11.8 Million
Q2 2023 Jul 26, 2023	SELL	$63.71 - $70.74 $645,509 - $716,737	-10,132 Reduced 4.47%	216,496 $13.8 Million
Q1 2023 Apr 19, 2023	BUY	$65.71 - $74.53 $132,077 - $149,805	2,010 Added 0.89%	226,628 $15.7 Million
Q4 2022 Jan 26, 2023	SELL	$68.48 - $81.09 $594,337 - $703,780	-8,679 Reduced 3.72%	224,618 $0
Q3 2022 Nov 17, 2022	SELL	$0.13 - $76.84 $154 - $91,132	-1,186 Reduced 0.51%	233,297 $16.6 Million
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $680,522 - $749,492	-9,371 Reduced 3.84%	234,483 $18.1 Million
Q1 2022 May 03, 2022	SELL	$61.48 - $73.72 $751,961 - $901,669	-12,231 Reduced 4.78%	243,854 $17.8 Million
Q4 2021 Feb 08, 2022	SELL	$53.63 - $62.52 $1.26 Million - $1.47 Million	-23,577 Reduced 8.43%	256,085 $16 Million
Q3 2021 Oct 19, 2021	BUY	$59.17 - $69.31 $4,911 - $5,752	83 Added 0.03%	279,662 $16.5 Million
Q2 2021 Jul 23, 2021	SELL	$61.91 - $67.42 $301,254 - $328,065	-4,866 Reduced 1.71%	279,579 $18.7 Million
Q1 2021 Apr 23, 2021	BUY	$59.34 - $66.74 $343,637 - $386,491	5,791 Added 2.08%	284,445 $18 Million
Q4 2020 Jan 29, 2021	SELL	$57.74 - $65.43 $164,154 - $186,017	-2,843 Reduced 1.01%	278,654 $17.3 Million
Q3 2020 Oct 22, 2020	BUY	$57.43 - $63.64 $821,708 - $910,561	14,308 Added 5.36%	281,497 $17 Million
Q2 2020 Jul 14, 2020	BUY	$54.82 - $64.09 $1.55 Million - $1.81 Million	28,292 Added 11.84%	267,189 $15.7 Million
Q1 2020 Apr 17, 2020	BUY	$46.4 - $67.43 $581,206 - $844,628	12,526 Added 5.53%	238,897 $13.3 Million
Q4 2019 Jan 21, 2020	BUY	$49.21 - $64.19 $3.89 Million - $5.07 Million	78,958 Added 53.56%	226,371 $14.5 Million
Q3 2019 Oct 28, 2019	SELL	$42.77 - $50.71 $68,175 - $80,831	-1,594 Reduced 1.07%	147,413 $7.48 Million
Q2 2019 Jul 12, 2019	SELL	$44.62 - $49.34 $21,640 - $23,929	-485 Reduced 0.32%	149,007 $0
Q1 2019 Apr 26, 2019	SELL	$45.12 - $53.8 $111,672 - $133,155	-2,475 Reduced 1.63%	149,492 $0
Q4 2018 Jan 08, 2019	SELL	$48.76 - $63.23 $356,240 - $461,958	-7,306 Reduced 4.59%	151,967 $7.9 Million
Q3 2018 Oct 04, 2018	SELL	$55.19 - $62.25 $130,800 - $147,532	-2,370 Reduced 1.47%	159,273 $0
Q2 2018 Jul 09, 2018	SELL	$50.53 - $62.98 $421,218 - $525,001	-8,336 Reduced 4.9%	161,643 $0
Q1 2018 Apr 04, 2018	SELL	$59.92 - $68.98 $742,768 - $855,076	-12,396 Reduced 6.8%	169,979 $0
Q4 2017 Jan 23, 2018	SELL	$59.94 - $65.35 $108,611 - $118,414	-1,812 Reduced 0.98%	182,375 $0
Q3 2017 Oct 17, 2017	BUY	$55.23 - $63.74 $10.2 Million - $11.7 Million	184,187	184,187 $0

Others Institutions Holding BMY

# of Institutions

2,620

Shares Held

1.46B

Call Options Held

31.5M

Put Options Held

34.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $122B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Central Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Central Trust CO with notifications on news.

Account